Clinical Trials
18 trialsNCT05468359 2026-05-19
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT03017326 2026-05-13
PHITT
University of Birmingham
Phase 3 Active not recruiting
NCT01840592 2026-05-06
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT00265798 2026-04-28
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02559778 2026-04-28
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT01871766 2026-04-24
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03164057 2026-04-23
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT01187199 2026-04-16
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03132454 2026-04-15
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01303341 2026-04-13
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01861314 2026-04-13
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05068752 2026-03-30
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Completed
NCT02298348 2026-03-23
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT03298451 2026-03-20
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT07463651 2026-03-20
TROPHY-15
The First Affiliated Hospital of Soochow University
Phase 3 Recruiting
NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT00939627 2026-03-10
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Phase 2 Completed